Biotech drug maker Gilead Sciences Inc. spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form.
The spending marks a 54 percent boost from $240,000 spend during the same period in 2008.
The company, based in Foster City, Calif., focused on HIV-related issues, including treatment, screening and education. Gilead sells the HIV drugs Atripla and Truvada, and makes the bulk of its revenue from those treatments.
Gilead also lobbied on global health and international trade issues, according to a form filed Jan. 20 with the House clerk's office.
Besides Congress, the company lobbied the departments of Commerce, Health and Human Services, and the National Institutes of Science in the October-December period.